Online inquiry

IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11444MR)

This product GTTS-WQ11444MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NT5E gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001204813.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4907
UniProt ID P21589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11444MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10834MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ10375MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ4732MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ3445MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ11757MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ475MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ1615MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ14849MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW